Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352361 | 0.88 | GABBR2 (0.39) | MGLLGABBR2GABBR1DGKAACHE | |
| SCHEMBL1038517 | 0.87 | MGLL (0.43) | MGLLDGKATSHRADRA2AADRA1A | |
| SCHEMBL1036029 | 0.86 | ACHE (0.41) | GABBR2GABBR1DGKAACHE | |
| SCHEMBL1036795 | 0.84 | MGLL (0.48) | MGLLGABBR2GABBR1DGKAACHE | |
| SCHEMBL4004473 | 0.81 | MGLL (0.39) | MGLLGABBR2GABBR1DGKATSHR | |
| SCHEMBL2173985 | 0.80 | MGLL (0.40) | MGLLDGKATSHRADRA2AADRA1A | |
| SCHEMBL2479531 | 0.79 | DGKA (0.42) | GABBR2GABBR1DGKAADRA2AADRA1A | |
| Ethylene Glycol SCHEMBL5407450 | 0.79 | MGLL (0.38) | MGLLGABBR2GABBR1DGKATSHR | |
| SCHEMBL2174627 | 0.79 | MGLL (0.39) | MGLLDGKAADRA2AADRA1ASMN1; SMN2 | |
| SCHEMBL258535 | 0.78 | THRB (0.49) | GABBR2GABBR1DGKATSHRADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832596-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT FINANCE BVI LTD (VG) | 2011-01-26 | — | — | EP | claimed |
| US-20070210288-A1 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | claimed |
| EP-1832596-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | claimed |
| US-8664418-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of acrylic acid derivatives and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-03-04 | — | — | US | disclosed |
| US-20110213052-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylic Acid Derivatives and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| EP-2352740-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLIC ACID DERIVATIVES AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-08-10 | — | — | EP | disclosed |
| EP-1832596-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT FINANCE BVI LTD (VG) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010051893-A1 | METHOD FOR PRODUCING DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLIC ACID DERIVATIVES AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-7485745-B2 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | CLARIANT INTERNATIONAL LTD. (CH) | 2009-02-03 | — | — | US | disclosed |
| US-20070210288-A1 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
| EP-1832596-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acids and other components | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213052-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylic Acid Derivatives and Use Thereof | ACSL3, HAO2, AOC3 | MGLL 35/4885GABBR2 1729/4885GABBR1 2192/4885 |
| US-20070210288-A1 | Mixtures composed of monocarboxy-functionalized dialkylphosphinic esters and of further components | ALKBH3, FFAR3, EBP | MGLL 95/4885GABBR2 343/4885GABBR1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.